Roche, Meiji Seika Pharma and Fedora have entered into a license agreement for the development and commercialization of OP0595, a beta-lactamase inhibitor in phase I clinical development.
Roche obtains worldwide rights from both companies for development and commercialization with the exception of Japan, where Meiji will retain sole commercialization rights.
Searching for more deal information? Current Partnering offers the following options:
|
Beta-lactamase inhibitors restore or potentiate the activity of beta-lactam antibiotics.
The combination of OP0595 with a beta-lactam antibiotic targets severe infections caused by Enterobacteriaceae, including multi-drug-resistant strains.
Meiji and Fedora will receive upfront plus development, regulatory and sales event milestone payments totaling potentially up to $750 million.
In addition, Meiji and Fedora are entitled to receive tiered royalties on sales of products originating from this collaboration.
For further deal information visit Current Agreements (subscription required)
Related
Scorecard: Top partnering deals by value in 2014
View: Top pharmaceutical companies
View: Top biotech companies
Report: Top 50 Big Pharma Partnering and M&A Deal Trends
Report: Top 50 Big Biotech Partnering and M&A Deal Trends
